מחקר ופרסומים

Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.

Leibowitz-Amit R(PI), Pintilie M(C), Khoja L(C), Azad AA(C), Berger R(C), Laird AD(C), Aftab DT(C), Chi KN(C), Joshua AM(PI).

TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma.

Roszik J(PI), Markovits E(C), Dobosz P(C), Layani A, Slabodnik-Kaner K(C), Baruch EN(C), Ben-Betzalel G(C), Grimm E(C), Berger R(C), Sidi Y(C), Schachter J(C), Shapira-Frommer R(C), Avni D(C), Markel G(C), Leibowitz-Amit R(PI).

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.

Motzer RJ(PI), Rini BI(C), McDermott DF(C), Arén Frontera O(C), Hammers HJ(C), Carducci MA(C), Salman P(C), Escudier B(C), Beuselinck B(C), Amin A(C), Porta C(C), George S(C), Neiman V(C), Bracarda S, Tykodi SS, Barthélémy P(C), Leibowitz-Amit R(C), Plimack ER(C), Oosting SF(C), Redman B(C), Melichar B(C), Powles T(C), Nathan P(C), Oudard S(C), Pook D(C), Choueiri TK(C), Donskov F(C), Grimm MO(C), Gurney H(C), Heng DYC(C), Kollmannsberger CK(C), Harrison MR(C), Tomita Y(C), Duran I(C), Grünwald V(C), McHenry MB(C), Mekan S(C), Tannir NM(PI); CheckMate 214 investigators.

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer.

Gadot M(PI), Davidson T(C), Aharon M(C), Atenafu EG(C), Malki A(C), Levartovsky M(C), Saad A(C), Domachevsky L(C), Berger R(C), Leibowitz R(PI).

A Retrospective Analysis of the Safety and Activity of Lutetium-177-Prostate-Specific Membrane Antigen Radionuclide Treatment in Older Patients with Metastatic Castration-Resistant Prostate Cancer.

Leibowitz R#(PI), Davidson T#(PI), Gadot M(C), Aharon M(C), Malki A(C), Levartovsky M(C), Oedegaard C(C), Saad A(C), Sandler I(C), Ben-Haim S(C), Domachevsky L(C), Berger R(PI). (#Equal contribution)

Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.

Gillessen S(PI), Armstrong A(C), Attard G(C), Beer TM(C), Beltran H(C), Bjartell A(C), Bossi A(C), Briganti A(C), Bristow RG(C), Bulbul M(C), Caffo O(C), Chi KN(C), Clarke CS(C), Clarke N(C), Davis ID(C), de Bono JS(C), Duran I(C), Eeles R(C), Efstathiou E(C), Efstathiou J(C), Ekeke ON(C), Evans C(C)P, Fanti S(C), Feng FY(C), Fizazi K(C), Frydenberg M(C), George D(C), Gleave M(C), Halabi S(C), Heinrich D(C), Higano C(C), Hofman MS(C), Hussain M(C), James N(C), Jones R(C), Kanesvaran R(C), Khauli RB(C), Klotz L(C), Leibowitz R(C), Logothetis C (C) Maluf F(C), Millman R(C), Morgans AK(C), Morris M(C)J, Mottet N(C), Mrabti H(C), Murphy DG(C), Murthy V(C), Oh WK(C), Ost P(C), O'Sullivan JM(C), Padhani AR, Parker C(C), Poon DMC(C), Pritchard CC(C), Rabah DM(C), Rathkopf D(C), Reiter RE(C), Rubin M(C), Ryan CJ(C), Saad F(C), Sade JP(C), Sartor O(C), Scher HI, Shore N(C), Skoneczna I(C), Small E(C), Smith M(C), Soule H(C), Spratt DE(C), Sternberg CN(C), Suzuki H(C), Sweeney C(C), Sydes MR(C), Taplin ME(C), Tilki D(C), Tombal B(C), Türkeri L(C), Uemura H(C), Uemura H(C), van Oort I(C), Yamoah K(C), Ye D(C), Zapatero A(C), Omlin A(PI).

Response to Anti-PD1/L1 Antibodies in Advanced Urothelial Cancer in the 'Real-Life' Setting.

Gadot M(PI), Arad I(C), Atenafu EG(C), Levartovsky M(C), Portnoy O(C), Davidson T(C), Schor-Bardach R(C), Berger R(C), Leibowitz R(PI).

Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.

Bar J#(PI), Leibowitz R#(PI), Reinmuth N(C), Ammendola A(C), Jacob E(C), Moskovitz M(C), Levy-Barda A(C), Lotem M(C), Katsenelson R(C), Agbarya A(C), Abu-Amna M(C), Gottfried M(C), Harkovsky T(C), Wolf I(C), Tepper E(C), Loewenthal G(C), Yellin B(C), Brody Y(C), Dahan N(C), Yanko M(C), Lahav C(C), Harel M(C), Raveh Shoval S(C), Elon Y, Sela I(C), Dicker AP(C), Shaked Y(PI). (# Equal contribution)

Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.

Christopoulos P(PI), Harel M(C), McGregor K(C), Brody Y(C), Puzanov I(C), Bar J(C), Elon Y(C), Sela I(C), Yellin B(C), Lahav C(C), Raveh S(C), Reiner-Benaim A(C), Reinmuth N(C), Nechushtan H(C), Farrugia D(C), Bustinza-Linares E(C), Lou Y(C), Leibowitz R(C), Kamer I(C), Zer Kuch A(C), Moskovitz M(C), Levy-Barda A(C), Koch I(C), Lotem M(C), Katzenelson R(C), Agbarya A(C), Price G(C), Cheley H(C), Abu-Amna M(C), Geldart T(C), Gottfried M(C), Tepper E(C), Polychronis A(C), Wolf I(C), Dicker AP(C), Carbone DP(C), Gandara DR(PI).

Prognostic immune logical implications of OX40L expression in the tumor microenvironment of melanoma.

Feldman S(PI), Da'ana B(C), Ofek N(C), Elkis L(C), Pollak-Moseri A(C), Riklin-Nahmias E(C), Mendlovic S(C), Avraham A#(PI), Leibowitz R#(PI). (# Equal contribution)